Coloplast (CPSE:COLO B) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

COLO B Aperçu des actions

Coloplast A/S développe et vend des produits et des services de soins intimes au Danemark, aux États-Unis, au Royaume-Uni, en France et dans le monde entier.

A propos de l'entreprise

COLO B analyse fondamentale
Score flocon de neige
Évaluation	3/6
Croissance future	2/6
Performances passées	2/6
Santé financière	1/6
Dividendes	3/6

Récompenses

Se négocie à 11.3% en dessous de notre estimation de sa juste valeur

Les bénéfices devraient augmenter 12.63% par an

Les revenus ont augmenté 4.9% par an au cours des 5 dernières années

Analyse des risques

La dette n’est pas bien couverte par le flux de trésorerie opérationnel

Le dividende de 2.37% n'est pas bien couvert par les bénéfices ou les flux de trésorerie disponibles

Les actionnaires ont été dilués au cours de l'année écoulée

Coloplast A/S Concurrents

Demant

CPSE:DEMANT

DKK 58.8b

Ambu

CPSE:AMBU B

DKK 40.7b

HOYA

TSE:7741

JP¥6.9t

Embla Medical hf

CPSE:EMBLA

DKK 13.2b

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Coloplast
Historique des cours de bourse
Prix actuel de l'action	DKK 900.80
Plus haut sur 52 semaines	DKK 977.60
Plus bas sur 52 semaines	DKK 689.20
Bêta	0.32
1Variation sur 1 mois	2.55%
Variation sur 3 mois	4.82%
Variation sur 1 an	12.94%
3Variation sur 3 ans	-17.92%
Variation sur 5 ans	11.79%
Évolution depuis l'introduction en bourse	6,949.74%

Nouvelles et mises à jour récentes

Subdued Growth No Barrier To Coloplast A/S' (CPH:COLO B) Price

Jul 17

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Jun 29

Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

May 21

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00

May 10

Recent updates

Subdued Growth No Barrier To Coloplast A/S' (CPH:COLO B) Price

Jul 17

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Jun 29

Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

May 21

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00

May 10

Analyst Estimates: Here's What Brokers Think Of Coloplast A/S (CPH:COLO B) After Its Interim Report

May 09

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Dec 04

Coloplast (CPH:COLO B) Strong Profits May Be Masking Some Underlying Issues

Nov 16

A Look At The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Sep 30

Is Coloplast (CPH:COLO B) A Risky Investment?

Jun 28

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 18% Below Its Share Price

Jun 10

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Mar 22

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 25% Below Its Share Price

Mar 01

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Dec 14

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Nov 26

Here's Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Looks Fair for the time being

Nov 25

Coloplast's (CPH:COLO B) Shareholders Will Receive A Bigger Dividend Than Last Year

Nov 11

With EPS Growth And More, Coloplast (CPH:COLO B) Makes An Interesting Case

Oct 25

Estimating The Fair Value Of Coloplast A/S (CPH:COLO B)

Aug 26

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Jul 27

Here's Why We Think Coloplast (CPH:COLO B) Is Well Worth Watching

Jul 12

Is There An Opportunity With Coloplast A/S' (CPH:COLO B) 45% Undervaluation?

May 23

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of kr.5.00

May 08

Coloplast (CPH:COLO B) Seems To Use Debt Rather Sparingly

Apr 13

Here's Why I Think Coloplast (CPH:COLO B) Is An Interesting Stock

Mar 29

Coloplast A/S (CPH:COLO B) Shares Could Be 41% Below Their Intrinsic Value Estimate

Feb 12

Coloplast (CPH:COLO B) Could Easily Take On More Debt

Jan 12

Is Now The Time To Put Coloplast (CPH:COLO B) On Your Watchlist?

Dec 28

Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Is Not Excessive At All

Nov 25

A Look At The Fair Value Of Coloplast A/S (CPH:COLO B)

Oct 31

Here's Why Coloplast (CPH:COLO B) Can Manage Its Debt Responsibly

Oct 02

Do Coloplast's (CPH:COLO B) Earnings Warrant Your Attention?

Sep 16

Does This Valuation Of Coloplast A/S (CPH:COLO B) Imply Investors Are Overpaying?

Aug 02

Rendement pour les actionnaires

	COLO B	DK Medical Equipment	DK Marché
7D	-2.1%	0.7%	-0.3%
1Y	12.9%	11.3%	25.4%

Rendement vs Industrie: COLO B a dépassé le secteur Danish Medical Equipment qui a rapporté 11.3 % au cours de l'année écoulée.

Rendement vs marché: COLO B a sous-performé le marché Danish qui a rapporté 27.3 % au cours de l'année écoulée.

Volatilité des prix

Is COLO B's price volatile compared to industry and market?
COLO B volatility
COLO B Average Weekly Movement	3.1%
Medical Equipment Industry Average Movement	5.7%
Market Average Movement	4.3%
10% most volatile stocks in DK Market	9.1%
10% least volatile stocks in DK Market	2.8%

Cours de l'action stable: COLO B n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de COLO B ( 3% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
1954	16,019	Kristian Villumsen	www.coloplast.com

Coloplast A/S développe et vend des produits et des services de soins intimes au Danemark, aux États-Unis, au Royaume-Uni, en France et dans le monde entier. La société opère à travers les segments Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, et Advanced Wound Care. Elle fournit des produits de soins pour stomies, notamment SenSura Mio, qui s'adapte aux formes corporelles individuelles et offre une discrétion optimale pour divers types de stomies, et SenSura Ostomy care solutions, ainsi que des accessoires pour stomies sous la marque Brava.

Coloplast A/S Résumé des fondamentaux

Comment les bénéfices et les revenus de Coloplast se comparent-ils à sa capitalisation boursière ?
COLO B statistiques fondamentales
Capitalisation boursière	DKK 199.61b
Bénéfices(TTM)	DKK 4.97b
Recettes(TTM)	DKK 26.30b

40.8x

Ratio P/E

7.7x

Ratio P/S

Le site COLO B est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
COLO B compte de résultat (TTM)
Recettes	DKK 26.30b
Coût des recettes	DKK 8.54b
Marge brute	DKK 17.76b
Autres dépenses	DKK 12.79b
Les revenus	DKK 4.97b

Derniers bénéfices déclarés

Jun 30, 2024

Prochaine date de publication des résultats

Nov 05, 2024

Résultat par action (EPS)	22.09
Marge brute	67.52%
Marge bénéficiaire nette	18.88%
Ratio dettes/capitaux propres	142.3%

Quelles ont été les performances à long terme de COLO B?

Voir les performances historiques et les comparaisons

Dividendes

2.3%

Rendement actuel des dividendes

95%

Ratio de distribution

COLO B Aperçu des actions

Récompenses

Analyse des risques

Coloplast A/S Concurrents

CPSE:DEMANT

DKK 58.8b

CPSE:AMBU B

DKK 40.7b

TSE:7741

JP¥6.9t

CPSE:EMBLA

DKK 13.2b

Historique des prix et performances

Nouvelles et mises à jour récentes

Third quarter 2024 earnings: EPS misses analyst expectations

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Subdued Growth No Barrier To Coloplast A/S' (CPH:COLO B) Price

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00

Recent updates

Third quarter 2024 earnings: EPS misses analyst expectations

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Subdued Growth No Barrier To Coloplast A/S' (CPH:COLO B) Price

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00

First half dividend of kr.5.00 announced

Analyst Estimates: Here's What Brokers Think Of Coloplast A/S (CPH:COLO B) After Its Interim Report

Coloplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24

Second quarter 2024 earnings: EPS misses analyst expectations

A Look At The Fair Value Of Coloplast A/S (CPH:COLO B)

There's Reason For Concern Over Coloplast A/S' (CPH:COLO B) Price

Is Coloplast (CPH:COLO B) A Risky Investment?

President & CEO exercised options and sold kr.13m worth of stock

First quarter 2024 earnings: Revenues in line with analyst expectations

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Estimating The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Coloplast A/S' (CPH:COLO B) Price Is Out Of Tune With Earnings

Coloplast A/S Approves the Distribution of Year-End Dividend

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast (CPH:COLO B) Strong Profits May Be Masking Some Underlying Issues

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Now 20% undervalued after recent price drop

A Look At The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Deputy Chairman recently bought kr.40m worth of stock

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

New minor risk - Shareholder dilution

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Is Coloplast (CPH:COLO B) A Risky Investment?

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 18% Below Its Share Price

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 25% Below Its Share Price

First quarter 2023 earnings: EPS misses analyst expectations

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Upcoming dividend of kr.15.00 per share

Here's Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Looks Fair for the time being

Less than half of directors are independent

Coloplast Announces Executive Changes

Coloplast's (CPH:COLO B) Shareholders Will Receive A Bigger Dividend Than Last Year

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

With EPS Growth And More, Coloplast (CPH:COLO B) Makes An Interesting Case

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Estimating The Fair Value Of Coloplast A/S (CPH:COLO B)

Third quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Here's Why We Think Coloplast (CPH:COLO B) Is Well Worth Watching

Is There An Opportunity With Coloplast A/S' (CPH:COLO B) 45% Undervaluation?